MétaCan
Menu
Back to cohort
Record W4399012115 · doi:10.1038/s41591-024-03015-5

Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial

2024· article· en· W4399012115 on OpenAlexfundno aff
Helen M. Colhoun, Ildiko Lingvay, Paul Brown, John Deanfield, Kirstine Brown‐Frandsen, Steven E. Kahn, Jorge Plutzky, Koichi Node, Alexander Parkhomenko, Lars Rydén, John Wilding, Johannes F.E. Mann, Katherine R. Tuttle, Thomas Idorn, Naveen Rathor, A. Michael Lincoff

Bibliographic record

VenueNature Medicine · 2024
Typearticle
Languageen
FieldMedicine
TopicDiabetes Treatment and Management
Canadian institutionsnot available
FundersDaiichi Sankyo EuropeMedical Research CouncilEli Lilly JapanMitsubishi Tanabe Pharma CorporationRelypsaTeijin PharmaShionogiNovo NordiskBayer HealthCareIntercept PharmaceuticalsNational Institutes of HealthMylanAstellas PharmaFibroGenMannKind CorporationCSL BehringNational Institute for Health and Care ResearchReCor MedicalIntarcia TherapeuticsBoehringer Ingelheim JapanPublic Health EnglandMcMaster UniversityEsperion TherapeuticsAlnylam PharmaceuticalsBritish Heart FoundationBrigham and Women's HospitalNovartis PharmaEuropean CommissionKowa CompanySanofiGlaxoSmithKlineNovo Nordisk PharmaAmgenPfizerBayer YakuhinCelgeneAstraZenecaOno PharmaceuticalEli Lilly and CompanyAkebia TherapeuticsBristol-Myers Squibb
KeywordsSemaglutideMedicineDiseaseObesityTerm (time)Internal medicineKidney diseaseIntensive care medicineDiabetes mellitusType 2 diabetesEndocrinologyLiraglutide

Abstract

fetched live from OpenAlex

Abstract The SELECT trial previously reported a 20% reduction in major adverse cardiovascular events with semaglutide ( n = 8,803) versus placebo ( n = 8,801) in patients with overweight/obesity and established cardiovascular disease, without diabetes. In the present study, we examined the effect of once-weekly semaglutide 2.4 mg on kidney outcomes in the SELECT trial. The incidence of the pre-specified main composite kidney endpoint (death from kidney disease, initiation of chronic kidney replacement therapy, onset of persistent estimated glomerular filtration rate (eGFR) < 15 ml min −1 1.73 m − 2 , persistent ≥50% reduction in eGFR or onset of persistent macroalbuminuria) was lower with semaglutide (1.8%) versus placebo (2.2%): hazard ratio (HR) = 0.78; 95% confidence interval (CI) 0.63, 0.96; P = 0.02. The treatment benefit at 104 weeks for eGFR was 0.75 ml min −1 1.73 m − 2 (95% CI 0.43, 1.06; P < 0.001) overall and 2.19 ml min −1 1.73 m − 2 (95% CI 1.00, 3.38; P < 0.001) in patients with baseline eGFR <60 ml min −1 1.73 m − 2 . These results suggest a benefit of semaglutide on kidney outcomes in individuals with overweight/obesity, without diabetes. ClinicalTrials.gov identifier: NCT03574597 .

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.048
Threshold uncertainty score0.324

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.010
GPT teacher head0.282
Teacher spread0.272 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations197
Published2024
Admission routes1
Has abstractyes

Explore more

Same venueNature MedicineSame topicDiabetes Treatment and ManagementFrench-language works237,207